Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.
A novel glycylcycline agent, tigecycline (GAR-936), was evaluated in vivo in the mouse model of peritonitis against three Enterococcus faecalis and four Enterococcus faecium isolates with different susceptibilities to vancomycin and tetracyclines, all of which were inhibited by </=0.125 micro g of tigecycline/ml. Using a single subcutaneous dose, tigecycline displayed a protective effect (50% protective dose, </=5.7 mg/kg of body weight) against all strains tested, including two with Tn925 (from the Tn916 family), which contains the Tet(M) tetracycline resistance determinant, as well as VanA and VanB strains. As expected, tetracycline and minocycline were ineffective against the isolates carrying Tn925.
Nannini
Esteban C
EC
Center for the Study of Emerging and Re-Emerging Pathogens, Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical School, Houston, Texas, USA. bem.asst@uth.tmc.edu
Pai
Suresh R
SR
Singh
Kavindra V
KV
Murray
Barbara E
BE
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D013293:Enterococcus faecalis / Q000187:drug effects*; D016984:Enterococcus faecium / Q000187:drug effects*; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D010538:Peritonitis / Q000188:drug therapy*; D013754:Tetracyclines / Q000494:pharmacology / Q000627:therapeutic use; D000078304:Tigecycline; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D013754:Tetracyclines; D014640:Vancomycin; D000078304:Tigecycline; D008911:Minocycline